Endi Lanza Galvão

Endi Lanza Galvão

Auto-generated profile, based on publicly available information

Endi Lanza Galvão

Universidade Federal dos Vales do Jequitinhonha e Mucuri

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2018 in Quality of Life Research
Verified
Journal Article
Closed access
PDF file
LDLucas Duarte-Rodrigues
Lucas Duarte-Rodrigues
EMEdnele Fabyene Primo Miranda
Ednele Fabyene Primo Miranda
TSTaiane Oliveira Souza
Taiane Oliveira Souza
HPHaroldo Neves de Paiva
Haroldo Neves de Paiva
SFSaulo Gabriel Moreira Falci
Saulo Gabriel Moreira Falci
EGEndi Lanza Galvão
Endi Lanza Galvão

9 October 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EGEndi Lanza Galvão
Endi Lanza Galvão
ARAna Rabello
Ana Rabello
GCGláucia Fernandes Cota
Gláucia Fernandes Cota
Several controlled and uncontrolled studies addressing azole antifungal drugs for cutaneous and mucosal leishmaniasis have been published with inconclusive results. We conducted a systematic literature review of studies evaluating the efficacy and toxicity associated with azole therapy for tegumentary leishmaniasis. PRISMA guidelines for systematic reviews and the Cochrane manual were followed, and the review methodology was registered (PROSPERO; CRD42016048668). Sources included the EMBASE, Web of Science, MEDLINE, LILACS, and IBECS databases along with a manual search of references from evaluated studies. Additional resources such as Google Scholar and clinicaltrials.gov were also searched. We included all studies reporting cure rate after cutaneous or mucosal leishmaniasis treatment with systemic azole drugs, regardless of their design. R software was used to estimate global rates of success and adverse events with each drug. The main outcome of interest was clinical cure, defined as complete re-epithelialization of all lesions. A total of 37 studies involving 1259 patients that reported outcomes after fluconazole (9), ketoconazole (14) and itraconazole (15) treatments were included. Only 14 (38%) were randomized controlled trials (RCT). The pooled azole final efficacy rate was 64% (CI95%: 57–70%) for all studies and 60% (CI95%: 50–70%) (p = 0.41) if only RCTs studies were considered. Twenty-four studies were conducted in the Old World and 13 studies in the Americas. The final efficacy rate according to New and Old World were 62% (CI95%: 43–77%) and 66% (CI95%: 58–73%), respectively. The final efficacy rate of azoles according to species were 89% (CI95%: 50–98%) for L. mexicana; 88% for L. infantum (CI95%: 27–99%); 80% for L. donovani; 53% (CI95%: 29–76%) for L. major; 49% for L. braziliensis (CI95%: 21–78%); and 15% (CI95%: 1–84%) for L. tropica. The cure rates were similar among the fluconazole, ketoconazole and itraconazole group arms (p = 0.89), specifically 61% (CI95%: 48–72%), 64% (CI95%: 44–80%) 65% (CI95%: 56–72%), respectively. Adverse events during fluconazole, itraconazole and ketoconazole therapy were reported in 7% (CI95%: 3–14%), 12% (CI95% 8–19%) and 13% (CI95%: 6–29%) of treated patients, respectively, without difference among them (p = 0.35). This systematic review included studies with small samples and both non-comparative and non-randomized studies and the main limitation was the low quality of the available studies. Available evidence suggests that fluconazole, ketoconazole and itraconazole have similar and modest efficacy rates for tegumentary leishmaniasis treatment. There is insufficient evidence to support the exclusive use of azole therapy as a single agent for leishmaniasis treatment.

1 November 2019 in Archives of Oral Biology
Verified
Journal Article
Closed access
EGEndi Lanza Galvão
Endi Lanza Galvão
ESEsmeralda Maria da Silveira
Esmeralda Maria da Silveira
EOEvandro Silveira de Oliveira
Evandro Silveira de Oliveira
TCTimilly Mayra Martins da Cruz
Timilly Mayra Martins da Cruz
OFOlga Dumont Flecha
Olga Dumont Flecha
PGPatricia Furtado Gonçalves
Patricia Furtado Gonçalves

20 February 2019 in Journal of Maxillofacial and Oral Surgery
Verified
Journal Article
Closed access
PDF file
APAna Cláudia Rocha Protásio
Ana Cláudia Rocha Protásio
EGEndi Lanza Galvão
Endi Lanza Galvão
SFSaulo Gabriel Moreira Falci
Saulo Gabriel Moreira Falci

16 April 2020 in BMC Oral Health
Verified
Journal Article
Open access
PDF file
BCBruna Almeida Silva Carvalho
Bruna Almeida Silva Carvalho
CDCésar Augusto Barroso Duarte
César Augusto Barroso Duarte
JSJaciara Fagundes Silva
Jaciara Fagundes Silva
WBWalter Winícius da Silva Batista
Walter Winícius da Silva Batista
DDDhelfeson Willya Douglas-De-Oliveira
Dhelfeson Willya Douglas-De-Oliveira
OFOlga Dumont Flecha
Olga Dumont Flecha
Background: The biologic width is defined as the coronal dimension to the alveolar bone that is occupied by healthy gingival tissue. The objective of the present study was to correlate radiographic findings of biologic width invasion with the periodontium status. Methods: It were included 14 patients with restored teeth with biological width invasion, on the proximal sites, observed clinically and radiographically. 122 proximal sites were evaluated, 61 in the test group (biological width invasion) and 61 in the control group (adequate biological width). Smokers and patients presenting periodontal disease or restorations with contact in eccentric movements, horizontal over-contour or secondary caries were excluded from the sample. The invasion of the biologic width was diagnosed when the distance from the gingival margin of restoration to the bony crest was less than 3 mm. Intrabony defect and bone crest level, as well as, their vertical and horizontal components were radiographically evaluated when present. Plaque index, bleeding on probing, probing depth, gingival recession height, keratinized gingival height and thickness, and clinical attachment level were clinically evaluated. Data were subjected to Spearman’s Correlation and Wilcoxon’s test. Result: The most prevalent tooth with biological width invasion was the first molar. There was a statistically significant correlation between the bone crest (p < 0.001), vertical (p < 0.001) and horizontal (p = 0.001) components. In the test group, there was a statistically significant correlation between bleeding on probing (p < 0.001; r = 0.618) and width of gingival recession (p = 0.030; r = − 0.602) with the intraosseous component; and between keratinized gingival height and bone level (p = 0.037; r = − 0.267). In the control group, there was a correlation between plaque index (p = 0.027; r = − 0.283) with bone level and correlation between keratinized gingival thickness and bone level (p = 0.034; r = − 0.273) and intrabony component (p = 0.042; r = 0.226). Conclusion: A statistically significant relationship was found between bleeding on probing and gingival recession in patients who presented intrabony defects due to the invasion of biological width, which may be also related to the thickness of the keratinized gingiva.

9 January 2022 in COPD: Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
DXDiêgo Mendes Xavier
Diêgo Mendes Xavier
EGEndi Lanza Galvão
Endi Lanza Galvão
AFAlenice Aliane Fonseca
Alenice Aliane Fonseca
GSGlaciele Maria de Souza
Glaciele Maria de Souza
VLVanessa Pereira Lima
Vanessa Pereira Lima
Conventional pulmonary rehabilitation programs are used as therapies for the treatment of chronic obstructive pulmonary disease (COPD). However, this modality presents barriers that make rehabilitation difficult. For this reason, home-based pulmonary rehabilitation (HBPR) has been used to overcome these barriers. The objective was to systematically compare a structured program with HBPR or a control group for participants with COPD. The primary outcome was an improvement in symptoms in the level of dyspnea and secondary outcomes were parameters in lung function, exercise capacity, health-related quality of life (HRQoL) and the impact of the disease on the individual. The Medline (via PubMed), Virtual Health Library and Cochrane Library databases were searched until May 10, 2021. Randomized controlled trials were included without restrictions on the year of publication or language. The risk of bias was evaluated using the Cochrane risk-of-bias tool for randomized trials (RoB). Our results showed that there was a significant decrease in the level of dyspnea, (MD: 5.46; 95% CI: 1.97 to 8.96), increased distance covered (MD: 61.75; 95% CI: 42, 94 to 80.56, significant improvement in HRQoL (MD: −11.30; 95% CI: −19.81 to −2.79) and reduction in the impact of the disease (DM: −4.71; 95% CI: −7.95 to −1.47). All results found were comparing the intervention group versus the control group. To conclude we found a reduction in the levels of dyspnea, an increase in the distance covered on the six-minute walk test, improving HRQoL and decreasing the impact of the disease in COPD patients in home-based pulmonary rehabilitation. Supplemental data for this article is available online at https://doi.org/10.1080/15412555.2021.2020234 .